Abstract
NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin-(1-7), AT1 receptor blockers, bradykinin, dihydropyridine calcium channel blockers, statins, endothelial nitric oxide synthase, nitric oxide, transcriptional and posttranscriptional regulation.
Current Pharmaceutical Design
Title:Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Volume: 23 Issue: 40
Author(s): Jin Bo Su*
Affiliation:
- Universite Paris-Est Creteil Val-de-Marne, 94700, Creteil,France
Keywords: Angiotensin-converting enzyme inhibitors, angiotensin-(1-7), AT1 receptor blockers, bradykinin, dihydropyridine calcium channel blockers, statins, endothelial nitric oxide synthase, nitric oxide, transcriptional and posttranscriptional regulation.
Abstract: NO produced by eNOS plays important roles in the cardiovascular system. Alterations in eNOS activity and expression occur in various cardiovascular disorders and eNOS constitutes a therapeutic target. In addition to posttranslational modifications of eNOS that affect eNOS activity, transcriptional and post-transcriptional regulation of eNOS expression also controls eNOS-derived NO production. Bradykinin is an important determinant of vascular function and participates in the regulation of eNOS activity and expression. A number of currently used drugs or investigational molecules targeting specific ion channels, enzymes or receptors, including dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibitors, statins, AT1 receptor blockers and angiotensin-(1-7), increase eNOS expression and activity. In this context, activation of bradykinin B2 receptors appears to be a common step for these drugs to promote eNOS expression, which certainly contributes to their therapeutic actions.
Export Options
About this article
Cite this article as:
Su Bo Jin*, Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666170622112253
DOI https://dx.doi.org/10.2174/1381612823666170622112253 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The Diagnostic and Prognostic Value of Brain Natriuretic Peptide and Aminoterminal (nt)-pro Brain Natriuretic Peptide
Current Pharmaceutical Design Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Current Pharmaceutical Design Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb
Current Medicinal Chemistry Creatine Supplementation: Can it Improve Quality of Life in the Elderly without Associated Resistance Training?
Current Aging Science Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets Chronic Heart Failure- Potential for Pharmacological Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Screening for Potential Bioactive Components in Ginkgo biloba Extract by the Rat Renal Tubular Epithelial Cell Extraction and LC-MS/MS
Combinatorial Chemistry & High Throughput Screening Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene and Stem Cell Therapy in the Treatment of Erectile Dysfunction and Pulmonary Hypertension; Potential Treatments for the Common Problem of Endothelial Dysfunction
Current Gene Therapy Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Nociceptin/Orphanin FQ Peptide Receptors: Pharmacology and Clinical Implications
Current Drug Targets Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?
Current Vascular Pharmacology Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine